Revenue Breakdown
Composition ()
No data
Revenue Streams
Pulse Biosciences Inc (PLSE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Systems, accounting for 78.9% of total sales, equivalent to $209.00K. Another important revenue stream is Cycle units. Understanding this composition is critical for investors evaluating how PLSE navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Pulse Biosciences Inc maintains a gross margin of -224.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23682.56%, while the net margin is -22540.70%. These profitability ratios, combined with a Return on Equity (ROE) of -86.99%, provide a clear picture of how effectively PLSE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PLSE competes directly with industry leaders such as STAA and INMD. With a market capitalization of $996.86M, it holds a leading position in the sector. When comparing efficiency, PLSE's gross margin of -224.42% stands against STAA's 82.21% and INMD's 77.61%. Such benchmarking helps identify whether Pulse Biosciences Inc is trading at a premium or discount relative to its financial performance.
